Yuki Kageyama to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Yuki Kageyama has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.741
-
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.
Score: 0.688
-
Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. Anticancer Res. 2022 Feb; 42(2):1131-1136.
Score: 0.589
-
Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Med. 2020 11; 9(22):8355-8363.
Score: 0.134
-
Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer. 2021 06; 19(3):208-216.e1.
Score: 0.132
-
Life-Threatening Tongue and Retropharyngeal Hemorrhage in a Patient with Hemophilia A with Inhibitors. Am J Case Rep. 2019 Jul 15; 20:1022-1026.
Score: 0.123
-
A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer. Gan To Kagaku Ryoho. 2023 Sep; 50(9):985-992.
Score: 0.041
-
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021 Mar; 70(3):657-665.
Score: 0.033